NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 4, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to...
Read MoreElective Interventional Procedures Resume in Germany NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 3, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina,...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, May 26, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering...
Read MoreNASDAQ, TSX: NVCN Company outlines milestone achievements towards value creation VANCOUVER and MINNEAPOLIS, May 26, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...
Read MorePromotes John Panton to Chief Quality Officer NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, May 7, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, May 1, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement and minimally invasive devices for the treatment of refractory angina, today announced that the Nasdaq Hearings...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, April 23, 2020 – Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for...
Read MoreNASDAQ, TSX: NVCN Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results VANCOUVER and MINNEAPOLIS, March 30, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the TiaraTM (“Tiara”), and minimally...
Read More